6 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18501729 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | HUTTER, GILLIAN A | 1625 | Final Rejection | Nov 03, 2023 |
| 18009172 | HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | SHIM, DAVID M. | 1626 | Non-Final OA | Jul 17, 2023 |
| 18009206 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | VAJDA, KRISTIN ANN | 1622 | Final Rejection | Dec 08, 2022 |
| 18009194 | 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | SHOWALTER, ALEXANDER KEITH | 1629 | Final Rejection | Dec 08, 2022 |
| 17756095 | DOSING REGIMENS FOR A PROTEIN KINASE C INHIBITOR | LEE, WILLIAM Y | 1623 | Non-Final OA | May 17, 2022 |
| 17761935 | 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS | SCHMIDT, IZABELA MARIA | 1621 | Final Rejection | Mar 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial